Spring Bank Pharmaceuticals, Inc.
Life Sciences Drug DevelopmentHopkinton, MA
Spring Bank Pharmaceuticals (“SBP”) is an Investigational New Drug (IND)-stage, drug discovery company. Based on its proprietary platform technology, SBP is developing a pipeline of products representing a “new class of pharmaceuticals” it calls small molecule nucleic acid hybrids (“SMNH”), which have a wide range of applications and multi-billion dollar market potential. These rationally designed molecules combine target selectivity and specificity advantages made possible by recent advances in genetic engineering, with the drug-like properties of classical pharmaceuticals, including oral delivery, good pharmacokinetics, low side effects and ease of manufacture. SBP’s most advanced product is SB 9200, a potential breakthrough drug for Hepatitis C and Hepatitis B that works in a unique way by activating the internal viral immune system of infected cells. SBP is planning to begin Phase I human trials in 2012. In addition SBP is currently using its platform SMNH technology to develop drugs for other viral infections such as RSV and Influenza, COPD and cancer. Since its founding in 2002, SBP has built its technology platform and product pipeline using a capital-efficient, semi-virtual business model, supported by $12M of non-dilutive National Institutes of Health (“NIH”) grants.